Acinetobacter baumannii nosocomial pneumonia: Is the outcome more favorable in non-ventilated than ventilated patients?

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Yang, Ya Sung ^a   Lee, Yi Tzu ^b,c   Huang, Tsai Wang ^a   Sun, Jun Ren ^a   Kuo, Shu Chen ^b,d   Yang, Chin Hsuan ^a   Chen, Te Li ^b   Lin, Jung Chung ^a   Fung, Chang Phone ^b   Chang, Feng Yee ^e  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e CENTER FOR DISEASE CONTROL   (Taiwan)

Author keywords

Acinectobacter baumannii; Hospital acquired; Pneumonia; Ventilator

Indexed keywords

CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; SULTAMICILLIN;

ACINETOBACTER INFECTION; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; CLINICAL FEATURE; CLONAL VARIATION; COMORBIDITY; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOLECULAR TYPING; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; TAIWAN; TEACHING HOSPITAL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; APACHE; COMORBIDITY; CROSS INFECTION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; ODDS RATIO; PHYLOGENY; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; TAIWAN; TREATMENT OUTCOME;

EID: 84875008370     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-142     Document Type: Article

References (33)

1. Luna CM, Aruj PK. Nosocomial Acinetobacter pneumonia. Respirology 2007, 12(6):787-791. 10.1111/j.1440-1843.2007.01147.x, 17986104.
2. Cisneros JM, Reyes MJ, Pachon J, Becerril B, Caballero FJ, Garcia-Garmendia JL, Ortiz C, Cobacho AR. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996, 22(6):1026-1032. 10.1093/clinids/22.6.1026, 8783704.
3. Garcia-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jimenez-Jimenez FJ, Perez-Paredes C, Barrero-Almodovar AE, Gili-Miner M. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis 2001, 33(7):939-946. 10.1086/322584, 11528563.
4. Levin AS, Levy CE, Manrique AE, Medeiros EA, Costa SF. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 2003, 21(1):58-62. 10.1016/S0924-8579(02)00276-5, 12507838.
5. Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 1995, 74(6):340-349.
6. Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005, 11(11):868-873. 10.1111/j.1469-0691.2005.01227.x, 16216100.
7. Lee YC, Huang YT, Tan CK, Kuo YW, Liao CH, Lee PI, Hsueh PR. Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: comparison of clinical features, prognostic factors and outcomes. J Antimicrob Chemother 2011, 66(8):1839-1846. 10.1093/jac/dkr200, 21653602.
8. Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents 2010, 35(3):219-226. 10.1016/j.ijantimicag.2009.10.024, 20047818.
9. Cerqueira GM, Peleg AY. Insights into Acinetobacter baumannii pathogenicity. IUBMB life 2011, 63(12):1055-1060. 10.1002/iub.533, 21989983.
10. Chuang YC, Sheng WH, Li SY, Lin YC, Wang JT, Chen YC, Chang SC. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with Acinetobacter bacteremia. Clin Infect Dis 2011, 52(3):352-360. 10.1093/cid/ciq154, 21193494.
11. Lee YT, Kuo SC, Yang SP, Lin YT, Tseng FC, Chen TL, Fung CP. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis 2012, 55(2):209-215. 10.1093/cid/cis385, 22495546.
12. Abrahamian FM, Deblieux PM, Emerman CL, Kollef MH, Kupersmith E, Leeper KV, Paterson DL, Shorr AF. Health care-associated pneumonia: identification and initial management in the ED. Am J Emerg Med 2008, 26(6 Suppl):1-11.
13. Chung DR, Song JH, Kim SH, Thamlikitkul V, Huang SG, Wang H, So TM, Yasin RM, Hsueh PR, Carlos CC. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 2011, 184(12):1409-1417. 10.1164/rccm.201102-0349OC, 21920919.
14. Ewig S, Bauer T, Torres A. The pulmonary physician in critical care * 4: Nosocomial pneumonia. Thorax 2002, 57(4):366-371. 10.1136/thorax.57.4.366, 1746297, 11923560.
15. Magret M, Lisboa T, Martin-Loeches I, Manez R, Nauwynck M, Wrigge H, Cardellino S, Diaz E, Koulenti D, Rello J. Bacteremia is an independent risk factor for mortality in nosocomial pneumonia: a prospective and observational multicenter study. Crit Care 2011, 15(1):R62. 10.1186/cc10036, 3221995, 21324159.
16. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171(4):388-416.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383. 10.1016/0021-9681(87)90171-8, 3558716.
18. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13(10):818-829. 10.1097/00003246-198510000-00009, 3928249.
19. Chen TL, Siu LK, Wu RC, Shaio MF, Huang LY, Fung CP, Lee CM, Cho WL. Comparison of one-tube multiplex PCR, automated ribotyping and intergenic spacer (ITS) sequencing for rapid identification of Acinetobacter baumannii. Clin Microbiol Infect 2007, 13(8):801-806. 10.1111/j.1469-0691.2007.01744.x, 17488329.
20. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: Twenty-first informational supplement 2011, CLSI, Wayne, PA: CLSI document M100-S21, Clinical and Laboratory Standards Institute (CLSI).
21. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008, 21(3):538-582. 10.1128/CMR.00058-07, 2493088, 18625687.
22. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995, 33(9):2233-2239. 228385, 7494007.
23. Esperatti M, Ferrer M, Theessen A, Liapikou A, Valencia M, Saucedo LM, Zavala E, Welte T, Torres A. Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. Am J Respir Crit Care Med 2010, 182(12):1533-1539. 10.1164/rccm.201001-0094OC, 20693381.
24. Sopena N, Sabria M, Neunos Study G. Multicenter study of hospital-acquired pneumonia in non-ICU patients. Chest 2005, 127(1):213-219. 10.1378/chest.127.1.213, 15653986.
25. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115(2):462-474. 10.1378/chest.115.2.462, 10027448.
26. Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Jolly EC. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997, 111(3):676-685. 10.1378/chest.111.3.676, 9118708.
27. Lynch JP. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 2001, 119(2 Suppl):373S-384S.
28. Brusselaers N, Labeau S, Vogelaers D, Blot S. Value of lower respiratory tract surveillance cultures to predict bacterial pathogens in ventilator-associated pneumonia: systematic review and diagnostic test accuracy meta-analysis. Intensive Care Med 2012,
29. Brusselaers N, Logie D, Vogelaers D, Monstrey S, Blot S. Burns, inhalation injury and ventilator-associated pneumonia: value of routine surveillance cultures. Burns: J Int Soc for Burn Injuries 2012, 38(3):364-370.
30. Kuo SC, Chang SC, Wang HY, Lai JF, Chen PC, Shiau YR, Huang IW, Lauderdale TL, Hospitals T. Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program. BMC Infect Dis 2012, 12:200. 10.1186/1471-2334-12-200, 3462144, 22929085.
31. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance?. Nat Rev Microbiol 2010, 8(4):260-271.
32. Kang YS, Park W. Trade-off between antibiotic resistance and biological fitness in Acinetobacter sp. strain DR1. Environmental Microbiol 2010, 12(5):1304-1318.
33. Chen SJ, Chao TF, Chiang MC, Kuo SC, Chen LY, Yin T, Chen TL, Fung CP. Prediction of patient outcome from Acinetobacter baumannii bacteremia with Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II scores. Intern Med 2011, 50(8):871-877. 10.2169/internalmedicine.50.4312, 21498935.